Research Analysts Issue Forecasts for SCYNEXIS FY2029 Earnings

SCYNEXIS, Inc. (NASDAQ:SCYX) – Investment analysts at Brookline Capital Management issued their FY2029 EPS estimates for shares of SCYNEXIS in a report issued on Thursday, March 13th. Brookline Capital Management analyst K. Dolliver anticipates that the company will earn $0.39 per share for the year.

SCYNEXIS (NASDAQ:SCYX) last posted its quarterly earnings results on Wednesday, March 12th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. SCYNEXIS had a negative net margin of 425.41% and a negative return on equity of 66.21%. The company had revenue of $0.98 million for the quarter.

Separately, StockNews.com lowered SCYNEXIS from a “hold” rating to a “sell” rating in a research note on Thursday.

SCYNEXIS Trading Up 8.6 %

Shares of SCYX opened at $0.93 on Monday. SCYNEXIS has a twelve month low of $0.82 and a twelve month high of $3.07. The firm has a market capitalization of $35.37 million, a P/E ratio of -1.26 and a beta of 1.67. The stock’s fifty day simple moving average is $1.08 and its 200 day simple moving average is $1.25.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Northern Trust Corp increased its position in shares of SCYNEXIS by 51.9% in the fourth quarter. Northern Trust Corp now owns 153,518 shares of the company’s stock worth $186,000 after acquiring an additional 52,466 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in SCYNEXIS during the 4th quarter worth $53,000. JPMorgan Chase & Co. acquired a new stake in SCYNEXIS in the 4th quarter valued at $49,000. Geode Capital Management LLC raised its position in SCYNEXIS by 10.0% in the third quarter. Geode Capital Management LLC now owns 398,856 shares of the company’s stock valued at $594,000 after purchasing an additional 36,405 shares during the period. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in SCYNEXIS by 22.0% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 195,393 shares of the company’s stock valued at $236,000 after purchasing an additional 35,233 shares during the period. 54.37% of the stock is owned by institutional investors and hedge funds.

SCYNEXIS Company Profile

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.